Literature DB >> 11295056

Characterization of CD44 splicing patterns in normal keratinocytes, dysplastic and squamous carcinoma cell lines.

B K Bloor1, M Jelvagharan, K N White, E W Odell.   

Abstract

The CD44 glycoprotein is spliced from a complex gene of 10 constitutive and 10 variant exons. In this study, CD44 splicing patterns and intron 9 retention were investigated by exon-specific RT-PCR for variant exons v1-v10 and intron 9 in normal, immortalized, dysplastic and malignant keratinocytes. Expression of product was determined immunohistochemically for some of the exons. Normal keratinocytes showed one major transcript including exons v2-v10 and 3 minor transcripts. No lines showed a normal CD44 splicing pattern but rather a variety of truncated transcripts of contiguous variant exons which overall correlated with expression. Squamous cell carcinoma (SCC)-4 and SCC-9 lines showed relatively normal transcripts although protein was expressed only by SCC-9. SCC-12B2, SCC-15, SCC-25 and SCC-27 showed a series of shorter overlapping transcripts, with loss of exons v8-v10 in the major transcripts. Intron 9 was not retained in normal keratinocytes or cell lines. Despite the fact that keratinocytes constitutively express all variant exons, splicing patterns are distinctly abnormal and merit investigation as potential markers for epidermal and oral squamous malignancy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11295056     DOI: 10.3892/ijo.18.5.1053

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  2 in total

1.  CD44 functions in Wnt signaling by regulating LRP6 localization and activation.

Authors:  M Schmitt; M Metzger; D Gradl; G Davidson; V Orian-Rousseau
Journal:  Cell Death Differ       Date:  2014-10-10       Impact factor: 15.828

2.  CD44 expression in oro-pharyngeal carcinoma tissues and cell lines.

Authors:  Abirami Rajarajan; Angela Stokes; Balvinder K Bloor; Rebecca Ceder; Hemini Desai; Roland C Grafström; Edward W Odell
Journal:  PLoS One       Date:  2012-01-05       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.